These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening. Hongo H; Kosaka T; Suzuki Y; Oya M Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):59-66. PubMed ID: 34593983 [TBL] [Abstract][Full Text] [Related]
9. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells. Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838 [TBL] [Abstract][Full Text] [Related]
10. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. Begemann D; Wang Y; Yang W; Kyprianou N Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812 [TBL] [Abstract][Full Text] [Related]
11. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells. Chao OS; Goodman OB Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853 [TBL] [Abstract][Full Text] [Related]
12. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328 [TBL] [Abstract][Full Text] [Related]
13. SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition. Aguilar-Valdés A; Noriega LG; Tovar AR; Ibarra-Sánchez MJ; Sosa-Hernández VA; Maravillas-Montero JL; Martínez-Aguilar J Biochem Biophys Res Commun; 2021 May; 552():23-29. PubMed ID: 33740661 [TBL] [Abstract][Full Text] [Related]
14. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer. Pungsrinont T; Kallenbach J; Baniahmad A Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745 [TBL] [Abstract][Full Text] [Related]
15. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Lu X; Yang F; Chen D; Zhao Q; Chen D; Ping H; Xing N Int J Biol Sci; 2020; 16(7):1121-1134. PubMed ID: 32174789 [TBL] [Abstract][Full Text] [Related]
16. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway. Dirican A; Atmaca H; Bozkurt E; Erten C; Karaca B; Uslu R Clin Transl Oncol; 2015 Feb; 17(2):145-51. PubMed ID: 25060568 [TBL] [Abstract][Full Text] [Related]
17. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865 [TBL] [Abstract][Full Text] [Related]
18. Insulin Mediated Activation of PI3K/Akt Signalling Pathway Modifies the Proteomic Cargo of Extracellular Vesicles. Liem M; Ang CS; Mathivanan S Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28842968 [TBL] [Abstract][Full Text] [Related]
19. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444 [TBL] [Abstract][Full Text] [Related]
20. Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. Wang P; Henning SM; Heber D; Vadgama JV J Nutr Biochem; 2015 Apr; 26(4):408-15. PubMed ID: 25655047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]